株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

世界の体外式膜型人工肺(ECMO)市場:モダリティ別、用途別、患者別、産業分析レポート、地域市場の見通し、用途可能性、価格動向、競合市場シェア、予測

Extracorporeal Membrane Oxygenation Market Size By Modality, By Application, By Patient Population, Industry Analysis Report, Regional Outlook, Application Potential, Price Trends, Competitive Market Share & Forecast, 2019 - 2025

発行 Global Market Insights Inc. 商品コード 701216
出版日 ページ情報 英文 141 Pages
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=109.88円で換算しております。
世界の体外式膜型人工肺(ECMO)市場:モダリティ別、用途別、患者別、産業分析レポート、地域市場の見通し、用途可能性、価格動向、競合市場シェア、予測 Extracorporeal Membrane Oxygenation Market Size By Modality, By Application, By Patient Population, Industry Analysis Report, Regional Outlook, Application Potential, Price Trends, Competitive Market Share & Forecast, 2019 - 2025
出版日: 2019年08月14日 ページ情報: 英文 141 Pages
概要

当レポートでは、世界の体外式膜型人工肺、通称ECMO(エクモ) 市場について調査分析を行い、市場概要、市場動向などについて考察するとともに、モダリティ別、用途別、患者別、地域別に市場を分析、主な企業のプロファイルなどについて包括的にまとめています。

第1章 調査方法と範囲

第2章 エグゼクティブサマリー

第3章 体外式膜型人工肺(ECMO)産業の考察

  • 産業セグメンテーション
  • 産業の状況
  • 産業影響因子
  • 成長性分析
  • 規制の状況
  • ファイブフォース分析
  • 競合状況
  • PESTEL分析

第4章 体外式膜型人工肺(ECMO)市場:モダリティ別

  • 体外式膜型人工肺(ECMO)市場シェア:モダリティ別
  • 静脈・動脈 (VA) 方式
  • 静脈・静脈 (VV) 方式
  • 動脈・静脈 (AV) 方式

第5章 体外式膜型人工肺(ECMO)市場:用途別

  • 体外式膜型人工肺(ECMO)市場シェア:用途別
  • 心臓疾患
  • 呼吸器疾患
  • 体外循環式心肺蘇生 (ECPR)

第6章 体外式膜型人工肺(ECMO)市場:患者別

  • 体外式膜型人工肺(ECMO)市場シェア:患者別
  • 乳幼児
  • 小児
  • 成人

第7章 体外式膜型人工肺(ECMO)市場:地域別

  • 体外式膜型人工肺(ECMO)市場シェア:地域別
  • 北米
  • 欧州
  • アジア太平洋地域
  • ラテンアメリカ
  • 中東/アフリカ

第8章 企業プロファイル

  • Abbott Laboratories
  • Alung Technologies
  • Braile Biomedic
  • Edwards Lifesciences Corp
  • Elsius Biomedical Inc.
  • Eurosets Srl
  • Getinge Group
  • LivaNova PLC
  • Medtronic Inc.
  • MicroPort Scientific Corporation
  • Nipro Corporation
  • Origen Biomedical
  • Spectrum Medical
  • Terumo Corporation

データ表

図表

Data Tables

  • TABLE 1 Extracorporeal membrane oxygenation industry 360 degree synopsis, 2014 - 2025
  • TABLE 2 Global extracorporeal membrane oxygenation market, 2014 - 2025 (USD Million)
  • TABLE 3 Global ECMO market, by modality, 2014 - 2025 (USD Million)
  • TABLE 4 Global ECMO market, by application, 2014 - 2025 (USD Million)
  • TABLE 5 Global ECMO market, by patient population, 2014 - 2025 (USD Million)
  • TABLE 6 Global ECMO market, by region, 2014 - 2025 (USD Million)
  • TABLE 7 Industry impact forces
  • TABLE 8 Venoarterial (VA) market, by region, 2014 - 2025, (USD Million)
  • TABLE 9 Veno-venous (VV)market, by region, 2014 - 2025, (USD Million)
  • TABLE 10 Arteriovenous (AV) market, by region, 2014 - 2025, (USD Million)
  • TABLE 11 Cardiac diseases market, by region, 2014 - 2025, (USD Million)
  • TABLE 12 Respiratory diseases market, by region, 2014 - 2025, (USD Million)
  • TABLE 13 ECPR market, by region, 2014 - 2025, (USD Million)
  • TABLE 14 Infant market, by region, 2014 - 2025, (USD Million)
  • TABLE 15 Pediatric market, by region, 2014 - 2025, (USD Million)
  • TABLE 16 Adult (VA) market, by region, 2014 - 2025, (USD Million)
  • TABLE 17 North America ECMO market, by country, 2014 - 2025 (USD Million)
  • TABLE 18 North America ECMO market, by modality, 2014 - 2025 (USD Million)
  • TABLE 19 North America ECMO market, by application, 2014 - 2025 (USD Million)
  • TABLE 20 North America ECMO market, by patient population, 2014 - 2025 (USD Million)
  • TABLE 21 U.S. ECMO market, by modality, 2014 - 2025 (USD Million)
  • TABLE 22 U.S. ECMO market, by application, 2014 - 2025 (USD Million)
  • TABLE 23 U.S. ECMO market, by patient population, 2014 - 2025 (USD Million)
  • TABLE 24 Canada ECMO market, by modality, 2014 - 2025 (USD Million)
  • TABLE 25 Canada ECMO market, by application, 2014 - 2025 (USD Million)
  • TABLE 26 Canada ECMO market, by patient population, 2014 - 2025 (USD Million)
  • TABLE 27 Europe ECMO market, by country, 2014 - 2025 (USD Million)
  • TABLE 28 Europe ECMO market, by modality, 2014 - 2025 (USD Million)
  • TABLE 29 Europe ECMO market, by application, 2014 - 2025 (USD Million)
  • TABLE 30 Europe ECMO market, by patient population, 2014 - 2025 (USD Million)
  • TABLE 31 Germany ECMO market, by modality, 2014 - 2025 (USD Million)
  • TABLE 32 Germany ECMO market, by application, 2014 - 2025 (USD Million)
  • TABLE 33 Germany ECMO market, by patient population, 2014 - 2025 (USD Million)
  • TABLE 34 UK ECMO market, by modality, 2014 - 2025 (USD Million)
  • TABLE 35 UK ECMO market, by application, 2014 - 2025 (USD Million)
  • TABLE 36 UK ECMO market, by patient population, 2014 - 2025 (USD Million)
  • TABLE 37 Italy ECMO market, by modality, 2014 - 2025 (USD Million)
  • TABLE 38 Italy ECMO market, by application, 2014 - 2025 (USD Million)
  • TABLE 39 Italy ECMO market, by patient population, 2014 - 2025 (USD Million)
  • TABLE 40 Spain ECMO market, by modality, 2014 - 2025 (USD Million)
  • TABLE 41 Spain ECMO market, by application, 2014 - 2025 (USD Million)
  • TABLE 42 Spain ECMO market, by patient population, 2014 - 2025 (USD Million)
  • TABLE 43 France ECMO market, by modality, 2014 - 2025 (USD Million)
  • TABLE 44 France ECMO market, by application, 2014 - 2025 (USD Million)
  • TABLE 45 France ECMO market, by patient population, 2014 - 2025 (USD Million)
  • TABLE 46 Asia Pacific ECMO market, by country, 2014 - 2025 (USD Million)
  • TABLE 47 Asia Pacific ECMO market, by modality, 2014 - 2025 (USD Million)
  • TABLE 48 Asia Pacific ECMO market, by application, 2014 - 2025 (USD Million)
  • TABLE 49 Asia Pacific ECMO market, by patient population, 2014 - 2025 (USD Million)
  • TABLE 50 China ECMO market, by modality, 2014 - 2025 (USD Million)
  • TABLE 51 China ECMO market, by application, 2014 - 2025 (USD Million)
  • TABLE 52 China ECMO market, by patient population, 2014 - 2025 (USD Million)
  • TABLE 53 India ECMO market, by modality, 2014 - 2025 (USD Million)
  • TABLE 54 India ECMO market, by application, 2014 - 2025 (USD Million)
  • TABLE 55 India ECMO market, by patient population, 2014 - 2025 (USD Million)
  • TABLE 56 Japan ECMO market, by modality, 2014 - 2025 (USD Million)
  • TABLE 57 Japan ECMO market, by application, 2014 - 2025 (USD Million)
  • TABLE 58 Japan ECMO market, by patient population, 2014 - 2025 (USD Million)
  • TABLE 59 Taiwan ECMO market, by modality, 2014 - 2025 (USD Million)
  • TABLE 60 Taiwan ECMO market, by application, 2014 - 2025 (USD Million)
  • TABLE 61 Taiwan ECMO market, by patient population, 2014 - 2025 (USD Million)
  • TABLE 62 Latin America ECMO market, by country 2014 - 2025 (USD Million)
  • TABLE 63 Latin America ECMO market, by modality, 2014 - 2025 (USD Million)
  • TABLE 64 Latin America ECMO market, by application, 2014 - 2025 (USD Million)
  • TABLE 65 Latin America ECMO market, by patient population, 2014 - 2025 (USD Million)
  • TABLE 66 Argentina ECMO market, by modality, 2014 - 2025 (USD Million)
  • TABLE 67 Argentina ECMO market, by application, 2014 - 2025 (USD Million)
  • TABLE 68 Argentina ECMO market, by patient population, 2014 - 2025 (USD Million)
  • TABLE 69 Brazil ECMO market, by modality, 2014 - 2025 (USD Million)
  • TABLE 70 Brazil ECMO market, by application, 2014 - 2025 (USD Million)
  • TABLE 71 Brazil ECMO market, by patient population, 2014 - 2025 (USD Million)
  • TABLE 72 Mexico ECMO market, by modality, 2014 - 2025 (USD Million)
  • TABLE 73 Mexico ECMO market, by application, 2014 - 2025 (USD Million)
  • TABLE 74 Mexico ECMO market, by patient population, 2014 - 2025 (USD Million)
  • TABLE 75 MEA ECMO market, by country 2014 - 2025 (USD Million)
  • TABLE 76 MEA ECMO market, by modality, 2014 - 2025 (USD Million)
  • TABLE 77 MEA ECMO market, by application, 2014 - 2025 (USD Million)
  • TABLE 78 MEA ECMO market, by patient population, 2014 - 2025 (USD Million)
  • TABLE 79 South Africa ECMO market, by modality, 2014 - 2025 (USD Million)
  • TABLE 80 South Africa ECMO market, by application, 2014 - 2025 (USD Million)
  • TABLE 81 South Africa ECMO market, by patient population, 2014 - 2025 (USD Million)
  • TABLE 82 UAE ECMO market, by modality, 2014 - 2025 (USD Million)
  • TABLE 83 UAE ECMO market, by application, 2014 - 2025 (USD Million)
  • TABLE 84 UAE ECMO market, by patient population, 2014 - 2025 (USD Million)
  • TABLE 85 Saudi Arabia ECMO market, by modality, 2014 - 2025 (USD Million)
  • TABLE 86 Saudi Arabia ECMO market, by application, 2014 - 2025 (USD Million)
  • TABLE 87 Saudi Arabia ECMO market, by patient population, 2014 - 2025 (USD Million)
  • TABLE 88 Qatar ECMO market, by modality, 2014 - 2025 (USD Million)
  • TABLE 89 Qatar ECMO market, by application, 2014 - 2025 (USD Million)
  • TABLE 90 Qatar ECMO market, by patient population, 2014 - 2025 (USD Million)

Charts & Figures

  • FIG. 1 Industry segmentation
  • FIG. 2 Global ECMO market, 2014 - 2025 (USD Million)
  • FIG. 3 Growth potential analysis, by modality
  • FIG. 4 Growth potential analysis, by application
  • FIG. 5 Growth potential analysis, by patient population
  • FIG. 6 Porter's analysis
  • FIG. 7 Strategic dashboard
  • FIG. 8 PESTEL analysis
目次
Product Code: 2720

Extracorporeal Membrane Oxygenation Market will exceed USD 370.0 million by 2025; as per a new research report.

Rising prevalence of respiratory disorders and growing adoption of extracorporeal membrane oxygenation procedure for the treatment will accelerate the growth of the ECMO market globally. Non-communicable diseases such as cardiovascular and chronic respiratory diseases are the main cause of mortality worldwide. According to the WHO, chronic obstructive pulmonary disease (COPD) affects nearly 200 million people globally.

Growing awareness about cardiovascular and respiratory conditions among the people and rising demand for better treatment procedures are the key factors propelling market growth for the given timeframe. Additionally, rising funding by government organizations for the treatment of chronic diseases will boost the market growth. For instance, in European Union the direct cost of COPD is around 6% of total health expenditure, accounting for nearly 56% of the total cost of respiratory diseases. Another, driving factor for extracorporeal membrane oxygenation market is high adoption rate of ECMO technique for lung transplantation. Thus, increasing awareness about extracorporeal membrane oxygenation technique among the patients and in hospitals will provide market players with better opportunity in the future.

High treatment cost of extracorporeal membrane oxygenation (ECMO) and lack of skilled medical practitioners will hamper the market growth over the coming years. In addition, high risk of complications such as infections, excessive bleeding, formation of blood clots and strokes due to use of ECMO system will restrain business growth to certain extent.

Veno-venous ECMO held over USD 105.0 million in the year 2018. Rising incidence of acute respiratory disease will augment the growth of veno-venous market. The veno venous ECMO offers complete respiratory support, low recirculation rate and less complications such as reduced bleeding. With successful application during treatment of H1N1 epidemic veno-venous technique is gaining popularity among the market players, thereby stimulating industry growth.

Rising use of ECMO in respiratory disease held substantial market share in 2018 with a total value of around USD 175 million. According to the WHO, asthma causes more than 1,80,000 deaths annually. The major share of this segment is attributed to increasing cases of pulmonary diseases, lung cancer and respiratory failure along with rising awareness about ECMO procedure.

Adult patient population segment will expand at 4.6% CAGR during the given timeline. Rising number of adults suffering from respiratory conditions especially in the emerging economies will act as primary factor for segmental growth. Tuberculosis is one of the leading causes of death among adults. According to WHO, mortality rate is 10 times higher in people more than 60 years than in people aged between 15 to 59. Thus, increasing cases of acute respiratory disorder and growing geriatric population base will play a major role towards growth of extracorporeal membrane oxygenation market worldwide.

Canada accounted for around 15% of North America ECMO market in 2018. Rising prevalence of cardiovascular diseases, advanced healthcare infrastructure and presence of skilled healthcare professionals in the country will lead to growth of Canada ECMO systems market during the projected period.

UK extracorporeal membrane oxygenation market was valued over USD 15.0 million in the year 2018. According to official statistics, respiratory disease is the third leading cause of death in the country. The economic burden of all lung conditions is around USD 12 billion annually in the UK. Therefore, rising incidence of respiratory disorders and growing awareness about ECMO procedure will propel market growth over the projected timeframe.

Some of the notable industry players are Medtronic, Getinge, Terumo, Abbott, LivaNova, and Alung Technologies, among others. Strategic collaborations and launch of advanced ECMO devices are the major strategies adopted by market players to strengthen their market position.

Table of Contents

Chapter 1. Methodology

  • 1.1. Methodology
  • 1.2. Market definitions
  • 1.3. Forecast parameters
  • 1.4. Data sources
    • 1.4.1. Secondary
      • 1.4.1.1. Paid sources
      • 1.4.1.2. Unpaid sources
    • 1.4.2. Primary

Chapter 2. Executive Summary

  • 2.1. Global extracorporeal membrane oxygenation industry 360 degree synopsis, 2014 - 2025
    • 2.1.1. Business trends
    • 2.1.2. Modality trends
    • 2.1.3. Application trends
    • 2.1.4. Patient population trends
    • 2.1.5. Regional trends

Chapter 3. Extracorporeal Membrane Oxygenation Industry Insights

  • 3.1. Industry segmentation
  • 3.2. Industry landscape, 2014 - 2025
  • 3.3. Industry impact forces
    • 3.3.1. Growth drivers
      • 3.3.1.1. Increase in cases of cardiopulmonary diseases and respiratory failure in Asia Pacific
      • 3.3.1.2. Technological advancements in ECMO device in North America
      • 3.3.1.3. Rising patient awareness about benefits delivered by extracorporeal membrane oxygenation device in Latin America
      • 3.3.1.4. Rising government initiatives and programs in Europe
    • 3.3.2. Industry pitfalls & challenges
      • 3.3.2.1. High costs of equipment
      • 3.3.2.2. Dearth of skilled professionals
      • 3.3.2.3. Risks related to ECMO device
  • 3.4. Growth potential analysis
    • 3.4.1. By modality
    • 3.4.2. By application
    • 3.4.3. By patient population
  • 3.5. Regulatory landscape
    • 3.5.1. U.S
    • 3.5.2. Europe
  • 3.6. Porter's analysis
  • 3.7. Competitive landscape, 2018
    • 3.7.1. Strategy dashboard
  • 3.8. PESTEL analysis

Chapter 4. Extracorporeal Membrane Oxygenation Market, By Modality

  • 4.1. Key segment trends
  • 4.2. Venoarterial (VA)
    • 4.2.1. Market size, by region, 2014 - 2025
  • 4.3. Veno-venous (VV)
    • 4.3.1. Market size, by region, 2014 - 2025
  • 4.4. Arteriovenous (AV)
    • 4.4.1. Market size, by region, 2014 - 2025

Chapter 5. Extracorporeal Membrane Oxygenation Market, By Application

  • 5.1. Key segment trends
  • 5.2. Cardiac diseases
    • 5.2.1. Market size, by region, 2014 - 2025
  • 5.3. Respiratory diseases
    • 5.3.1. Market size, by region, 2014 - 2025
  • 5.4. Extracorporeal cardiopulmonary resuscitation (ECPR)
    • 5.4.1. Market size, by region, 2014 - 2025

Chapter 6. Extracorporeal Membrane Oxygenation Market, By Patient Population

  • 6.1. Key segment trends
  • 6.2. Infant
    • 6.2.1. Market size, by region, 2014 - 2025
  • 6.3. Pediatric
    • 6.3.1. Market size, by region, 2014 - 2025
  • 6.4. Adult
    • 6.4.1. Market size, by region, 2014 - 2025

Chapter 7. Extracorporeal Membrane Oxygenation Market, By Region

  • 7.1. Key regional trends
  • 7.2. North America
    • 7.2.1. Market size, by country, 2014 - 2025
    • 7.2.2. Market size, by modality, 2014 - 2025
    • 7.2.3. Market size, by application, 2014 - 2025
    • 7.2.4. Market size, by patient population, 2014 - 2025
    • 7.2.5. U.S.
      • 7.2.5.1. Market size, by modality, 2014 - 2025
      • 7.2.5.2. Market size, by application, 2014 - 2025
      • 7.2.5.3. Market size, by patient population, 2014 - 2025
    • 7.2.6. Canada
      • 7.2.6.1. Market size, by modality, 2014 - 2025
      • 7.2.6.2. Market size, by application, 2014 - 2025
      • 7.2.6.3. Market size, by patient population, 2014 - 2025
  • 7.3. Europe
    • 7.3.1. Market size, by country, 2014 - 2025
    • 7.3.2. Market size, by modality, 2014 - 2025
    • 7.3.3. Market size, by application, 2014 - 2025
    • 7.3.4. Market size, by patient population, 2014 - 2025
    • 7.3.5. Germany
      • 7.3.5.1. Market size, by modality, 2014 - 2025
      • 7.3.5.2. Market size, by application, 2014 - 2025
      • 7.3.5.3. Market size, by patient population, 2014 - 2025
    • 7.3.6. UK
      • 7.3.6.1. Market size, by modality, 2014 - 2025
      • 7.3.6.2. Market size, by application, 2014 - 2025
      • 7.3.6.3. Market size, by patient population, 2014 - 2025
    • 7.3.7. France
      • 7.3.7.1. Market size, by modality, 2014 - 2025
      • 7.3.7.2. Market size, by application, 2014 - 2025
      • 7.3.7.3. Market size, by patient population, 2014 - 2025
    • 7.3.8. Italy
      • 7.3.8.1. Market size, by modality, 2014 - 2025
      • 7.3.8.2. Market size, by application, 2014 - 2025
      • 7.3.8.3. Market size, by patient population, 2014 - 2025
    • 7.3.9. Spain
      • 7.3.9.1. Market size, by modality, 2014 - 2025
      • 7.3.9.2. Market size, by application, 2014 - 2025
      • 7.3.9.3. Market size, by patient population, 2014 - 2025
  • 7.4. Asia Pacific
    • 7.4.1. Market size, by country, 2014 - 2025
    • 7.4.2. Market size, by modality, 2014 - 2025
    • 7.4.3. Market size, by application, 2014 - 2025
    • 7.4.4. Market size, by patient population, 2014 - 2025
    • 7.4.5. Japan
      • 7.4.5.1. Market size, by modality, 2014 - 2025
      • 7.4.5.2. Market size, by application, 2014 - 2025
      • 7.4.5.3. Market size, by patient population, 2014 - 2025
    • 7.4.6. China
      • 7.4.6.1. Market size, by modality, 2014 - 2025
      • 7.4.6.2. Market size, by application, 2014 - 2025
      • 7.4.6.3. Market size, by patient population, 2014 - 2025
    • 7.4.7. India
      • 7.4.7.1. Market size, by modality, 2014 - 2025
      • 7.4.7.2. Market size, by application, 2014 - 2025
      • 7.4.7.3. Market size, by patient population, 2014 - 2025
    • 7.4.8. Taiwan
      • 7.4.8.1. Market size, by modality, 2014 - 2025
      • 7.4.8.2. Market size, by application, 2014 - 2025
      • 7.4.8.3. Market size, by patient population, 2014 - 2025
  • 7.5. Latin America
    • 7.5.1. Market size, by country, 2014 - 2025
    • 7.5.2. Market size, by modality, 2014 - 2025
    • 7.5.3. Market size, by application, 2014 - 2025
    • 7.5.4. Market size, by patient population, 2014 - 2025
    • 7.5.5. Brazil
      • 7.5.5.1. Market size, by modality, 2014 - 2025
      • 7.5.5.2. Market size, by application, 2014 - 2025
      • 7.5.5.3. Market size, by patient population, 2014 - 2025
    • 7.5.6. Mexico
      • 7.5.6.1. Market size, by modality, 2014 - 2025
      • 7.5.6.2. Market size, by application, 2014 - 2025
      • 7.5.6.3. Market size, by patient population, 2014 - 2025
    • 7.5.7. Argentina
      • 7.5.7.1. Market size, by modality, 2014 - 2025
      • 7.5.7.2. Market size, by application, 2014 - 2025
      • 7.5.7.3. Market size, by patient population, 2014 - 2025
  • 7.6. Middle East & Africa
    • 7.6.1. Market size, by country, 2014 - 2025
    • 7.6.2. Market size, by modality, 2014 - 2025
    • 7.6.3. Market size, by application, 2014 - 2025
    • 7.6.4. Market size, by patient population, 2014 - 2025
    • 7.6.5. Saudi Arabia
      • 7.6.5.1. Market size, by modality, 2014 - 2025
      • 7.6.5.2. Market size, by application, 2014 - 2025
      • 7.6.5.3. Market size, by patient population, 2014 - 2025
    • 7.6.6. Qatar
      • 7.6.6.1. Market size, by modality, 2014 - 2025
      • 7.6.6.2. Market size, by application, 2014 - 2025
      • 7.6.6.3. Market size, by patient population, 2014 - 2025
    • 7.6.7. UAE
      • 7.6.7.1. Market size, by modality, 2014 - 2025
      • 7.6.7.2. Market size, by application, 2014 - 2025
      • 7.6.7.3. Market size, by patient population, 2014 - 2025
    • 7.6.8. South Africa
      • 7.6.8.1. Market size, by modality, 2014 - 2025
      • 7.6.8.2. Market size, by application, 2014 - 2025
      • 7.6.8.3. Market size, by patient population, 2014 - 2025

Chapter 8. Company Profiles

  • 8.1. Abbott Laboratories
    • 8.1.1. Business overview
    • 8.1.2. Financial data
    • 8.1.3. Product landscape
    • 8.1.4. Strategic outlook
    • 8.1.5. SWOT analysis
  • 8.2. Alung Technologies
    • 8.2.1. Business overview
    • 8.2.2. Financial data
    • 8.2.3. Product landscape
    • 8.2.4. Strategic outlook
    • 8.2.5. SWOT analysis
  • 8.3. Braile Biomedical
    • 8.3.1. Business overview
    • 8.3.2. Financial data
    • 8.3.3. Product landscape
    • 8.3.4. Strategic outlook
    • 8.3.5. SWOT analysis
  • 8.4. Edwards Lifesciences Corp
    • 8.4.1. Business overview
    • 8.4.2. Financial data
    • 8.4.3. Product landscape
    • 8.4.4. Strategic outlook
    • 8.4.5. SWOT analysis
  • 8.5. Elsius Biomedical Inc.
    • 8.5.1. Business overview
    • 8.5.2. Financial data
    • 8.5.3. Product landscape
    • 8.5.4. Strategic outlook
    • 8.5.5. SWOT analysis
  • 8.6. Eurosets Srl
    • 8.6.1. Business overview
    • 8.6.2. Financial data
    • 8.6.3. Product landscape
    • 8.6.4. Strategic outlook
    • 8.6.5. SWOT analysis
  • 8.7. Getinge Group
    • 8.7.1. Business overview
    • 8.7.2. Financial data
    • 8.7.3. Product landscape
    • 8.7.4. Strategic outlook
    • 8.7.5. SWOT analysis
  • 8.8. LivaNova PLC
    • 8.8.1. Business overview
    • 8.8.2. Financial data
    • 8.8.3. Product landscape
    • 8.8.4. Strategic outlook
    • 8.8.5. SWOT analysis
  • 8.9. Medtronic Inc.
    • 8.9.1. Business overview
    • 8.9.2. Financial data
    • 8.9.3. Product landscape
    • 8.9.4. Strategic outlook
    • 8.9.5. SWOT analysis
  • 8.10. MicroPort Scientific Corporation
    • 8.10.1. Business overview
    • 8.10.2. Financial data
    • 8.10.3. Product landscape
    • 8.10.4. Strategic outlook
    • 8.10.5. SWOT analysis
  • 8.11. Nipro Corporation
    • 8.11.1. Business overview
    • 8.11.2. Financial data
    • 8.11.3. Product landscape
    • 8.11.4. Strategic outlook
    • 8.11.5. SWOT analysis
  • 8.12. Origen Biomedical
    • 8.12.1. Business overview
    • 8.12.2. Financial data
    • 8.12.3. Product landscape
    • 8.12.4. Strategic outlook
    • 8.12.5. SWOT analysis
  • 8.13. Spectrum Medical
    • 8.13.1. Business overview
    • 8.13.2. Financial data
    • 8.13.3. Product landscape
    • 8.13.4. Strategic outlook
    • 8.13.5. SWOT analysis
  • 8.14. Terumo Corporation
    • 8.14.1. Business overview
    • 8.14.2. Financial data
    • 8.14.3. Product landscape
    • 8.14.4. Strategic outlook
    • 8.14.5. SWOT analysis